Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: A review

被引：47

作者：

Kaur, Maninder ^{[1
]}

Singh, Manjinder ^{[1
]}

Silakari, Om ^{[1
]}

机构：

[1] Punjabi Univ, Dept Pharmaceut Sci & Drug Res, MML, Patiala 147002, Punjab, India

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2013年 / 67卷

关键词：

Autoimmune diseases; Inflammation; Spleen tyrosine kinase; Asthma; Psoriasis; B-Cell lymphoma; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MAST-CELL ACTIVATION; NF-KAPPA-B; SYK-KINASE; POTENT INHIBITORS; SH2; DOMAINS; AUTOIMMUNE; TARGET; DAMAGE; TRANSCRIPTION;

D O I：

10.1016/j.ejmech.2013.04.070

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Spleen tyrosine kinase (Syk), a member of Syk family of non-receptor protein tyrosine kinases plays a significant role in the immune cell signaling in B cells, mast cells, macrophages and neutrophils. Anomalous regulation of this kinase can lead to different allergic disorders and antibody-mediated autoimmune diseases such as rheumatoid arthritis, asthma, psoriasis and allergic rhinitis. Being involved in the growth and survive mechanism of B cells, its inhibition can be beneficial in B-cell lymphoma. Thus, Syk can be sited as a therapeutically relevant target for various allergic and autoimmune disorders. This review article describes the structure of Syk and its role in B-cell signaling. In addition to this, data regarding small molecule inhibitors of Syk has also been reviewed from different papers and patents published. (C) 2013 Elsevier Masson SAS. All rights reserved.

引用

页码：434 / 446

页数：13

共 89 条

[1] GASTROINTESTINAL DAMAGE ASSOCIATED WITH THE USE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS [J].

ALLISON, MC ;

HOWATSON, AG ;

TORRANCE, CJ ;

LEE, FD ;

RUSSELL, RI .

NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (11) :749-754

[2] Protein kinase C-θ (PKCθ):: it's all about location, location, location [J].

Altman, A ;

Villalba, M .

IMMUNOLOGICAL REVIEWS, 2003, 192 (01) :53-63

[3]

Ancliff R.A., 2006, Patent No. [EP1948659 A1, 1948659]

[4] Piceatannol inhibits TNF-induced NF-κB activation and NF-κB-mediated gene expression through suppression of IκBα kinase and p65 phosphorylation [J].

Ashikawa, K ;

Majumdar, S ;

Banerjee, S ;

Bharti, AC ;

Shishodia, S ;

Aggarwal, BB .

JOURNAL OF IMMUNOLOGY, 2002, 169 (11) :6490-6497

[5]

Atkinson F.L., 2007, Patent No. [WO2007/085540, 2007085540]

[6]

Baenteli R., 2006, U.S. Patent, Patent No. [7671063, 767106316]

[7] An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus [J].

Bahjat, Frances Rena ;

Pine, Polly R. ;

Reitsma, Andrea ;

Cassafer, Gail ;

Baluom, Muhammad ;

Grillo, Sunny ;

Chang, Betty ;

Zhao, Fei Fei ;

Payan, Donald G. ;

Grossbard, Elliott B. ;

Daikh, David I. .

ARTHRITIS AND RHEUMATISM, 2008, 58 (05) :1433-1444

[8] Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis [J].

Bajpai, Malini ;

Chopra, Puneet ;

Dastidar, Sunanda G. ;

Ray, Abhijit .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (05) :641-659

[9]

Bajpai M, 2009, IDRUGS, V12, P174

[10]

Bhamidipati S., 2012, U.S. Patent, Patent No. [8211889, 821188912]

← 1 2 3 4 5 6 7 8 9 →